Cronos Group Inc.

Cronos Group Inc. Earnings Recaps

CRON Health Care 1 recap
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Nov 7, 2026

Cronos shares rose 6.0% after the company reported record Q3 net revenue, gross profit and Adjusted EBITDA, alongside strong growth in Israel, Canada and other international markets. The Netherlands acquisition adds a longer-term opportunity, though management expects price compression as suppliers ramp up.

Key takeaways
  • Israel net revenue grew 33% year over year, or 19% on a constant-currency basis, marking an 11th consecutive quarterly record.
  • Canadian net revenue reached a record; Cronos brands’ retail sales grew 41% year over year versus 1% industry-wide. Spinach held the top vape position, while SOURZ remained the leading edible brand.
  • Revenue in international markets outside Israel rose sevenfold year over year, from $1.9 million to $13.2 million, led by Germany.
  • Cronos completed its CanAdelaar acquisition in October. Management sees potential in new product formats and operational efficiencies, but says the Dutch market is immature and expects price compression as supply increases.